Chk1 inhibition combined with standard dose gemcitabine may be safe and effective

Investigational PD-L1–targeted immunotherapy safe for patients with triple-negative breast cancer, effective in some

BRAF 'behind the scenes' in melanoma: A scientific story of discovery

Connecting science, practice and patient outcomes: Use of BRAF inhibitors for treating metastatic melanoma in clinical practice

Targeting CDK pathways in cancer treatment

DNA repair inhibitors to overcome drug resistance

Refining the role of PARP inhibitors in targeted anticancer therapy

Developments in immunotherapy

Discovering selective anticancer drugs: succeeding slowly is better than failing fast

Putting adoptive T cell therapy on the path to regulatory approval

Using Hsp90 inhibitors in the clinic: what have we learned?

Radiogenomic evaluation of tumour response to targeted agents